DURECT Co. (NASDAQ:DRRX) Director Jon S. Saxe purchased 25,000 shares of the stock in a transaction on Monday, June 10th. The stock was acquired at an average cost of $0.55 per share, for a total transaction of $13,750.00. Following the completion of the acquisition, the director now owns 27,810 shares of the company’s stock, valued at approximately $15,295.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ:DRRX traded up $0.01 during mid-day trading on Friday, hitting $0.52. The company’s stock had a trading volume of 3,435 shares, compared to its average volume of 502,647. DURECT Co. has a 1 year low of $0.46 and a 1 year high of $2.24. The company has a debt-to-equity ratio of 1.82, a quick ratio of 3.39 and a current ratio of 3.74. The firm has a market cap of $85.14 million, a price-to-earnings ratio of -3.30 and a beta of 1.89.
DURECT (NASDAQ:DRRX) last posted its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. DURECT had a negative net margin of 125.76% and a negative return on equity of 108.92%. The company had revenue of $4.13 million for the quarter, compared to analyst estimates of $3.50 million. As a group, equities research analysts predict that DURECT Co. will post -0.19 earnings per share for the current fiscal year.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $3.50 price target on shares of DURECT in a report on Thursday, May 9th.
DURECT Company Profile
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand.
Featured Story: Book Value Per Share – BVPS
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.